James Jones bought $862 of CPIX
director at CUMBERLAND PHARMACEUTICALS INC. 262 shares at an average of $3.29, traded Aug 1, 2025, filed Sep 12, 2025.
Score components
- +15RoleDirector
- 0Trade size$862 at market
- -5Relative to holdingsUnder 1% of holdings (0.6%)
- +8Price context48% below the 52-week high
- +15Cluster4 insiders buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
- -1510b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +0.3%, 3m -26.5%, 6m -11.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-041987, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 1, 2025 | POpen-market purchase Common Stock10b5-1 | +13 | $3.44 | $45 | 43,689 | Sep 12, 2025 |
| Aug 4, 2025 | POpen-market purchase Common Stock10b5-1 | +13 | $4.01 | $52 | 43,702 | Sep 12, 2025 |
| Aug 5, 2025 | POpen-market purchase Common Stock10b5-1 | +13 | $3.92 | $51 | 43,715 | Sep 12, 2025 |
| Aug 6, 2025 | POpen-market purchase Common Stock10b5-1 | +13 | $3.34 | $43 | 43,728 | Sep 12, 2025 |
| Aug 7, 2025 | POpen-market purchase Common Stock10b5-1 | +13 | $3.14 | $41 | 43,741 | Sep 12, 2025 |
| Aug 8, 2025 | POpen-market purchase Common Stock10b5-1 | +13 | $3.39 | $44 | 43,754 | Sep 12, 2025 |
| Aug 11, 2025 | POpen-market purchase Common Stock10b5-1 | +13 | $2.87 | $37 | 43,767 | Sep 12, 2025 |
| Aug 12, 2025 | POpen-market purchase Common Stock10b5-1 | +13 | $2.91 | $38 | 43,780 | Sep 12, 2025 |
| Aug 13, 2025 | POpen-market purchase Common Stock10b5-1 | +13 | $2.94 | $38 | 43,793 | Sep 12, 2025 |
| Aug 14, 2025 | POpen-market purchase Common Stock10b5-1 | +13 | $2.84 | $37 | 43,806 | Sep 12, 2025 |
| Aug 15, 2025 | POpen-market purchase Common Stock10b5-1 | +13 | $3.02 | $39 | 43,819 | Sep 12, 2025 |
| Aug 18, 2025 | POpen-market purchase Common Stock10b5-1 | +13 | $3.11 | $40 | 43,832 | Sep 12, 2025 |
| Aug 19, 2025 | POpen-market purchase Common Stock10b5-1 | +13 | $3.23 | $42 | 43,845 | Sep 12, 2025 |
| Aug 20, 2025 | POpen-market purchase Common Stock10b5-1 | +2 | $3.15 | $6 | 43,847 | Sep 12, 2025 |
| Aug 21, 2025 | POpen-market purchase Common Stock10b5-1 | +13 | $3.25 | $42 | 43,860 | Sep 12, 2025 |
| Aug 22, 2025 | POpen-market purchase Common Stock10b5-1 | +13 | $3.31 | $43 | 43,873 | Sep 12, 2025 |
| Aug 25, 2025 | POpen-market purchase Common Stock10b5-1 | +13 | $3.32 | $43 | 43,886 | Sep 12, 2025 |
| Aug 26, 2025 | POpen-market purchase Common Stock10b5-1 | +13 | $3.39 | $44 | 43,899 | Sep 12, 2025 |
| Aug 27, 2025 | POpen-market purchase Common Stock10b5-1 | +13 | $3.44 | $45 | 43,912 | Sep 12, 2025 |
| Aug 28, 2025 | POpen-market purchase Common Stock10b5-1 | +13 | $3.47 | $45 | 43,925 | Sep 12, 2025 |
| Aug 29, 2025 | POpen-market purchase Common Stock10b5-1 | +13 | $3.45 | $45 | 43,938 | Sep 12, 2025 |
Related signals
Other insiders at CUMBERLAND PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $4,516 1,372 shares | +0% | |
| 33Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $862 262 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Caroline Young director | $398 121 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $5,872 1,712 shares | +1% | |
| 33Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $1,166 340 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | James Jones director | $1,166 340 shares | +1% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Caroline Young director | $578 168 shares | +1% | |
| 19Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $4,513 935 shares | +0% | |
| 19Weak | CUMBERLAND PHARMACEUTICALS INC | James Jones director | $807 168 shares | +0% | |
| 29Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $807 168 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.